|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003923 |
Purpose
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas.
PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating patients who have cancer of the bile duct, gallbladder, or pancreas.
| Condition | Intervention | Phase |
|---|---|---|
|
Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer Pancreatic Cancer |
Drug: porfimer sodium |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction |
| Estimated Enrollment: | 30 |
| Study Start Date: | March 1999 |
OBJECTIVES: I. Determine the safety and efficacy of photodynamic therapy using porfimer sodium in patients with unresectable malignant bile duct obstruction.
OUTLINE: Patients are stratified according to tumor location (proximal vs distal). Patients receive porfimer sodium IV over 3-5 minutes on day 1, followed by percutaneous or endoscopic laser light treatment on day 3.
Patients achieving partial response or complete response accompanied by an increase in total bilirubin or cholangitis may repeat treatment for a maximum of 3 courses. Patients are followed weekly for 1 month, and then monthly for 1 year.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically proven malignant bile duct obstruction with obstructive jaundice Primary carcinoma of bile duct, gallbladder, or pancreas OR Metastatic bile duct disease Successful insertion of a percutaneous drain or endoscopic stent Unresectable disease OR Resectable disease but refusal of surgery Prior biliary plastic or metallic stent allowed, if requiring stent replacement due to recurrent jaundice or routine plastic stent change No erosion of biliary tumors into major blood vessels No evidence of bile duct perforation
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin at least 2 mg/dL Renal: Not specified Other: No history of allergies or hypersensitivity to porphyrins No porphyria No cholangitis or pancreatitis
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy or brachytherapy to the abdomen Surgery: See Disease Characteristics Other: No other prior or concurrent experimental or investigational drugs
Contacts and Locations| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | |
| New York, New York, United States, 10021 | |
| Study Chair: | Hans Gerdes, MD | Memorial Sloan-Kettering Cancer Center |
More Information
| Study ID Numbers: | CDR0000067110, MSKCC-99015, NCI-G99-1525 |
| Study First Received: | November 1, 1999 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00003923 History of Changes |
| Health Authority: | United States: Federal Government |
|
stage I pancreatic cancer stage II pancreatic cancer stage III pancreatic cancer stage IV pancreatic cancer recurrent pancreatic cancer unresectable gallbladder cancer |
recurrent gallbladder cancer unresectable extrahepatic bile duct cancer recurrent extrahepatic bile duct cancer cholangiocarcinoma of the gallbladder cholangiocarcinoma of the extrahepatic bile duct adult primary cholangiocellular carcinoma |
|
Gallbladder Diseases Liver Diseases Cholestasis Pancreatic Neoplasms Bile Duct Cancer, Extrahepatic Pancrelipase Liver Neoplasms Biliary Tract Diseases Hematoporphyrin Derivative Trioxsalen Endocrine Gland Neoplasms Cholangiocarcinoma Digestive System Neoplasms Biliary Tract Neoplasms |
Endocrine System Diseases Recurrence Carcinoma Gall Bladder Cancer Photosensitizing Agents Digestive System Diseases Radiation-Sensitizing Agents Bile Duct Diseases Dihematoporphyrin Ether Gastrointestinal Neoplasms Pancreatic Diseases Bile Duct Neoplasms Gallbladder Neoplasms Endocrinopathy |
|
Gallbladder Diseases Liver Diseases Antineoplastic Agents Pancreatic Neoplasms Physiological Effects of Drugs Liver Neoplasms Neoplasms by Site Biliary Tract Diseases Therapeutic Uses Trioxsalen Dermatologic Agents Endocrine Gland Neoplasms Digestive System Neoplasms |
Biliary Tract Neoplasms Endocrine System Diseases Pharmacologic Actions Neoplasms Photosensitizing Agents Digestive System Diseases Radiation-Sensitizing Agents Bile Duct Diseases Dihematoporphyrin Ether Pancreatic Diseases Bile Duct Neoplasms Gallbladder Neoplasms |
